Second Affiliated Hospital of Zhejiang University

Running trials

• Not yet recruiting

  Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence

  NCT07901842· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

  NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source

• Not yet recruiting

  Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic Stroke

  NCT07609654· Phase 4· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

  NCT07244978· Phase 2· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury

  NCT07760038· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

  NCT07321873· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

  NCT07302360· Xian-Janssen Pharmaceutical Ltd.· Source

• Recruiting

  Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury

  NCT07263217· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Research on the Protective Effects of Phycocyanin Against Liver Fibrosis and Cirrhosis

  NCT07271576· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

  NCT06862869· Hoffmann-La Roche· Source

• Not yet recruiting

  Deep Sedation in Catheter Ablation of Atrial Fibrillation

  NCT06836999· The First Affiliated Hospital of Dalian Medical University· Source

• Not yet recruiting

  A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

  NCT06766552· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Intravenous Thrombolysis and NOAC

  NCT06749834· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Liposomal Irinotecan and Apatinib in ES-SCLC

  NCT06749691· Phase 2· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer

  NCT06658080· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging

  NCT06681155· Chinese PLA General Hospital· Source

• Recruiting

  ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

  NCT06825624· Phase 1· Hansoh BioMedical R&D Company· Source

• Active, not recruiting

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06508658· Phase 3· Genmab· Source

• Recruiting

  A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

  NCT06240689· Phase 2· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)

  NCT06220617· Zhejiang University· Source

• Recruiting

  Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage

  NCT05595603· Phase 2· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery

  NCT06164769· Zhejiang University· Source

• Not yet recruiting

  Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study

  NCT05602974· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

  NCT05307835· Phase 1· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)

  NCT04624295· Phase 4· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  RFA Plus Carrizumab vs Carrizumab Alone for HCC

  NCT04150744· Phase 2· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer

  NCT03498326· Phase 2· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Clinical Outcomes Following Primary Intracerebral Hemorrhage

  NCT06548737· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Comparison Influence to Prognosis of CTP and MRP in AIS Patients

  NCT03367286· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk

  NCT00289380· Peking Union Medical College· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke6 recruiting
• Liver and biliary tract cancer4 recruiting
• Colorectal cancer3 recruiting
• Atrial fibrillation2 recruiting
• Childhood cancers2 recruiting
• Lung cancer2 recruiting
• Pancreatic cancer2 recruiting
• Ankylosing spondylitis1 recruiting
• Coronary artery disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver cirrhosis1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

  NCT05247203· Phase 1· RemeGen Co., Ltd.· Source

• Completed

  A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

  NCT05029921· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

  NCT03898180· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

  NCT03750669· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

Trial sites

• Department of Neurology, the Second Affiliated Hospital of Zhejiang University, School of Medicine2 trials
• Second Affiliated Hospital of Zhejiang University2 trials
• Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou1 trial
• Second Affiliated Hospital, Zhejiang University1 trial
• Second Affiliated Hospital, Zhejiang University - Binjiang Campus /ID# 2431371 trial
• Second Affiliated Hospital, Zhejiang University (Site 0734)1 trial
• The Second Affiliated Hospital of Zhejiang University27 trials
• The Second Affiliated Hospital, Zhejiang University3 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Colorectal cancer118 works · 3 trials
• Lung cancer112 works · 2 trials
• Liver and biliary tract cancer86 works · 4 trials
• Parkinson disease68 works · 0 trials
• Asthma46 works · 0 trials
• Psoriasis44 works · 2 trials
• Osteoarthritis43 works · 0 trials
• Gastric and oesophageal cancer43 works · 2 trials
• Epilepsy40 works · 0 trials
• Pancreatic cancer38 works · 3 trials
• Sarcoma31 works · 0 trials
• Crohn's disease30 works · 2 trials
• Glioblastoma29 works · 0 trials
• Ulcerative colitis29 works · 2 trials
• Lupus (SLE)25 works · 1 trial
• COPD25 works · 0 trials
• Triple-negative breast cancer23 works · 0 trials
• Osteoporosis22 works · 0 trials
• Glaucoma19 works · 0 trials
• Atopic dermatitis (eczema)18 works · 0 trials
• Diabetic eye disease17 works · 0 trials
• Macular degeneration15 works · 0 trials
• Aortic stenosis14 works · 0 trials
• Idiopathic pulmonary fibrosis11 works · 0 trials
• Diffuse large B-cell lymphoma10 works · 1 trial
• Alopecia areata8 works · 0 trials
• Peripheral artery disease7 works · 0 trials
• Essential tremor7 works · 0 trials
• Dilated cardiomyopathy7 works · 0 trials
• Multiple system atrophy7 works · 0 trials